Research graph
References from Rational design of D(+)-biotin-conjugated resorcinol dibenzyl ethers as tumor-targeted PD-L1 inhibitors for precision cancer immunotherapy. Local targets link to admitted publications; unresolved targets remain external evidence.
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
10.1016/j.semcancer.2015.03.004 · 2015 · External reference
Cancer immunotherapy: the beginning of the end of cancer
10.1186/s12916-016-0623-5 · 2016 · External reference
Immuno-Oncology: Emerging targets and combination therapies
10.3389/fonc.2018.00315 · 2018 · External reference
PD-L1: expression regulation
10.1097/bs9.0000000000000149 · 2023 · External reference
PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition
10.3389/fimmu.2019.02022 · 2019 · External reference
Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway
10.1038/s41401-020-0366-x · 2021 · External reference
Beyond peptides: Unveiling the design strategies, structure activity correlations and protein-ligand interactions of small molecule inhibitors against PD-1/PD-L1
10.1016/j.bioorg.2024.108036 · 2025 · External reference
Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction
10.1016/j.bmc.2022.117001 · 2022 · External reference
Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens
10.21147/j.issn.1000-9604.2018.02.01 · 2018 · External reference
Immune checkpoint inhibitors in cancer therapy
10.7555/jbr.31.20160168 · 2018 · External reference
Role of the PD-1 pathway in the immune response
10.1111/j.1600-6143.2012.04224.x · 2012 · External reference
Recent advances in developing targeted protein degraders
10.1016/j.ejmech.2024.117212 · 2024 · External reference
Research progress in bifunctional small molecules for cancer immunotherapy
10.1016/j.ejmech.2025.117289 · 2025 · External reference
Roles of PD-1/PD-L1 pathway: Signaling, cancer, and beyond
10.1007/978-981-15-3266-5_3 · 2020 · External reference
Design, synthesis, and pharmacological evaluation of biaryl-containing PD-1/PD-L1 interaction inhibitors bearing a unique difluoromethyleneoxy linkage
10.1021/acs.jmedchem.1c01422 · 2021 · External reference
Discovery of highly potent small-molecule PD-1/PD-L1 inhibitors with a novel scaffold for cancer immunotherapy
10.1021/acs.jmedchem.3c02362 · 2024 · External reference
Reducing PD-L1 expression by degraders and downregulators as a novel strategy to target the PD-1/PD-L1 pathway
10.1021/acs.jmedchem.3c02143 · 2024 · External reference
Discovery of novel d-(+)-biotin-conjugated resorcinol dibenzyl ether-based PD-L1 inhibitors for targeted cancer immunotherapy
10.1021/acs.jmedchem.3c00479 · 2023 · External reference
Probing biotin receptors in cancer cells with rationally designed fluorogenic squaraine dimers
10.1039/d0sc01973a · 2020 · External reference
Biotin-mediated drug delivery: does the biotin transporter mediate uptake of biotin conjugates
10.1080/14756366.2025.2554896 · 2025 · External reference
Biotin uptake by T47D breast cancer cells: functional and molecular evidence of sodium-dependent multivitamin transporter (SMVT)
10.1016/j.ijpharm.2012.10.047 · 2013 · External reference
Discovery of novel heterotricyclic compounds as DNA-dependent protein kinase (DNA-PK) inhibitors with enhanced chemosensitivity, oral bioavailability, and the ability to potentiate cancer immunotherapy
10.1021/acs.jmedchem.3c02231 · 2024 · External reference
Discovery of novel heterotetracyclic DNA-dependent protein kinase (DNA-PK) inhibitors with improved oral bioavailability and potent cancer immunotherapy-potentiating activity
10.1021/acs.jmedchem.5c03630 · 2026 · External reference
Spop-binding bifunctional degraders: a novel approach for cancer immunotherapy
10.1016/j.jare.2025.11.042 · 2025 · External reference
